Aligos Therapeutics (ALGS) Price & Analysis

Compare

226 Followers

ALGS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.76 - $46.80

Previous CloseN/A

Volume178.18K

Average Volume (3M)74.95K

Market Cap

$64.90M

Enterprise Value-$41.55M

Total Cash (Recent Filing)$123.06M

Total Debt (Recent Filing)$6.88M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Oct 30, 2025

EPS Estimate

-1.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.53

Shares Outstanding5,351,374

10 Day Avg. Volume99,735

30 Day Avg. Volume74,952

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.64

Enterprise Value/Revenue-13.09

Enterprise Value/Gross Profit-18.51

Enterprise Value/Ebitda0.57

Forecast

1Y Price Target

$50.00

Price Target Upside370.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressWith written regulatory guidance and a global Phase 2 trial underway, ALG-000184 has a de-risked path to approval and potential to redefine the chronic HBV treatment landscape.

Safety ProfileALG-000184 showed a favorable safety profile, with no viral breakthroughs or known CAM-resistant mutations reported with ALG-000184 monotherapy treatment.

Therapeutic PotentialALG-000184 has the potential to become the new standard-of-care for chronic suppression of hepatitis B virus (HBV), serving as the oral backbone to future functional cure regimens.

Bears Say

Clinical EffectivenessThe initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.

Market CompetitionALG-000184 is positioned to displace nucleos(t)ide analogs (NUCs) as the foundation of chronic HBV infection management.

Regulatory ChallengesAligos is moving toward a more attainable goal, and one that is expected to be supported and endorsed by the FDA, EMA, and NMPA.

Aligos Therapeutics News

Aligos Therapeutics appoints Ramon Polo as head of global regulatory affairs

Aligos Therapeutics (ALGS) announced the appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs,...

15d ago

ALGS

Aligos Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Aligos Therapeutics (ALGS) with a Buy rating and $50 price target The firm...

17d ago

ALGS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

20d ago

ALGS

Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study

Aligos Therapeutics (ALGS) announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has...

22d ago

ALGS

Aligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)

Reports Q2 revenue $965,000, consensus $433,330. “Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway...

29d ago

ALGS

Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth

Patrick Trucchio, an analyst from H.C. Wainwright, has initiated a new Buy rating on Aligos Therapeutics (ALGS). Patrick...

16d ago

ALGS

Aligos Therapeutics Reports Q2 2025 Progress and Results

Aligos Therapeutics, Inc. ( ($ALGS) ) has released its Q2 earnings. Here is a breakdown of the information...

28d ago

ALGS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

2M ago

ALGS

Aligos Therapeutics Approves Major Amendments at Annual Meeting

An update from Aligos Therapeutics ( ($ALGS) ) is now available. On June 25, 2025, Aligos Therapeutics, Inc....

2M ago

ALGS

Aligos Therapeutics appoints Kieron Wesson as VP, head of CMC

Aligos Therapeutics (ALGS) announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls,...

3M ago

ALGS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options...

3M ago

ALGS

Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal

Aligos Therapeutics (ALGS) announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately....

4M ago

ALGS

CDXS

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock...

4M ago

ALGS

Aligos Therapeutics Reports Strong Q1 2025 Progress

Aligos Therapeutics, Inc. ( ($ALGS) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

ALGS

ALGS FAQ

What was Aligos Therapeutics’s price range in the past 12 months?

Aligos Therapeutics lowest stock price was $3.76 and its highest was $46.80 in the past 12 months.

What is Aligos Therapeutics’s market cap?

Aligos Therapeutics’s market cap is $64.90M.

When is Aligos Therapeutics’s upcoming earnings report date?

Aligos Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 56 days.

How were Aligos Therapeutics’s earnings last quarter?

Aligos Therapeutics released its earnings results on Aug 06, 2025. The company reported -$1.53 earnings per share for the quarter, beating the consensus estimate of -$2.363 by $0.833.

Is Aligos Therapeutics overvalued?

According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aligos Therapeutics pay dividends?

Aligos Therapeutics does not currently pay dividends.

What is Aligos Therapeutics’s EPS estimate?

Aligos Therapeutics’s EPS estimate is -1.9.

How many shares outstanding does Aligos Therapeutics have?

Aligos Therapeutics has 5,351,374 shares outstanding.

What happened to Aligos Therapeutics’s price movement after its last earnings report?

Aligos Therapeutics reported an EPS of -$1.53 in its last earnings report, beating expectations of -$2.363. Following the earnings report the stock price went up 1.119%.

Which hedge fund is a major shareholder of Aligos Therapeutics?

Currently, no hedge funds are holding shares in ALGS

Aligos Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-87.74%

Trailing 12-Months

Asset Growth

23.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aligos Therapeutics

Aligos Therapeutics (ALGS) is a clinical-stage biopharmaceutical company specializing in the development of targeted antiviral therapies for chronic liver diseases and other viral infections. The company focuses primarily on discovering and advancing small molecule and oligonucleotide-based therapeutics. Aligos's core research and development efforts are directed towards treating hepatitis B virus (HBV) infections, nonalcoholic steatohepatitis (NASH), and coronaviruses, leveraging their expertise in virology and liver disease.

Aligos Therapeutics (ALGS) Earnings & Revenues

Historic Earnings Reports

ALGS Stock 12 Month Forecast

Average Price Target

$50.00

▲(370.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","51":"$51","15.75":"$15.75","27.5":"$27.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15.75,27.5,39.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,10.732307692307693,14.004615384615384,17.276923076923076,20.549230769230768,23.821538461538463,27.093846153846155,30.366153846153846,33.638461538461534,36.910769230769226,40.183076923076925,43.45538461538462,46.72769230769231,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,10.732307692307693,14.004615384615384,17.276923076923076,20.549230769230768,23.821538461538463,27.093846153846155,30.366153846153846,33.638461538461534,36.910769230769226,40.183076923076925,43.45538461538462,46.72769230769231,{"y":50,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.46,10.732307692307693,14.004615384615384,17.276923076923076,20.549230769230768,23.821538461538463,27.093846153846155,30.366153846153846,33.638461538461534,36.910769230769226,40.183076923076925,43.45538461538462,46.72769230769231,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.25,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.87,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >